A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (goserelin acetate implant) 10.8 mg and ZOLADEX® (goserelin acetate implant) 3.6 mg in Chinese Patients with Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

Study identifier:D8664R00001

ClinicalTrials.gov identifier:NCT03193060

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (goserelin acetate implant) 10.8 mg and ZOLADEX® (goserelin acetate implant) 3.6 mg in Chinese Patients with Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer

Medical condition

Localized or locally advanced prostate cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

Male

Actual Enrollment

308

Study type

Observational

Age

18 Years - 100 Years

Date

Study Start Date: 19 Sept 2017
Primary Completion Date: 27 Dec 2019
Study Completion Date: 27 Dec 2019

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jul 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria